LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy.

    Ledergor, Guy / Fan, Zenghua / Wu, Kai / McCarthy, Elizabeth / Hyrenius-Wittsten, Axel / Starzinski, Alec / Chang, Hewitt / Bridge, Mark / Kwek, Serena S / Cheung, Alexander / Bylsma, Sophia Anna / Hansen, Erik / Wolf, Jeffrey Lee / Wong, Sandy W / Shah, Nina / Roybal, Kole T / Martin, Thomas G / Ye, Chun Jimmie / Fong, Lawrence

    Blood advances

    2024  

    Abstract: Multiple myeloma is characterized by frequent clinical relapses following conventional therapy. Recently, chimeric antigen receptor T (CAR-T) cells targeting B-cell maturation antigen (BCMA) has been established as a treatment option for patients with ... ...

    Abstract Multiple myeloma is characterized by frequent clinical relapses following conventional therapy. Recently, chimeric antigen receptor T (CAR-T) cells targeting B-cell maturation antigen (BCMA) has been established as a treatment option for patients with relapsed or refractory disease. However, while >70% of patients initially respond to this treatment, clinical relapse and disease progression occur in most cases. Recent studies showed persistent expression of BCMA at the time of relapse, indicating that immune intrinsic mechanisms may contribute to this resistance. While there were no pre-existing T cell features associated with clinical outcomes, we found that patients with a durable response to CAR-T cell treatment had greater persistence of their CAR-T cells compared to patients with transient clinical responses. They also possessed a significantly higher proportion of CD8+ T effector memory cells. In contrast, patients with short-lived responses to treatment have increased frequencies of cytotoxic CD4+ CAR-T cells. These cells expand in vivo early after infusion but express exhaustion markers (HAVCR2 and TIGIT) and remain polyclonal. Finally, we demonstrate that non-classical monocytes are enriched in the myeloma niche and may induce CAR-T cell dysfunction through mechanisms that include TGFβ. These findings shed new light on the role of cytotoxic CD4+ T cells in disease progression after CAR-T cell therapy.
    Language English
    Publishing date 2024-04-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023012416
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The VEGF Treatment of AMD Switch Study (The vTAS Study).

    Curry, Beverley / Bylsma, Guy / Hewitt, Alex W / Verma, Nitin

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)

    2017  Volume 6, Issue 6, Page(s) 481–487

    Abstract: Purpose: To evaluate the effect of aflibercept on anatomic and visual outcomes in patients with choroidal neovascularization (CNV) previously treated with intravitreal ranibizumab with persistent fluid on optical coherence tomography (OCT).: Design: ... ...

    Abstract Purpose: To evaluate the effect of aflibercept on anatomic and visual outcomes in patients with choroidal neovascularization (CNV) previously treated with intravitreal ranibizumab with persistent fluid on optical coherence tomography (OCT).
    Design: Prospective, open-label study.
    Methods: Eighteen patients (19 eyes) with CNV being treated with monthly ranibizumab, with persistent fluid on OCT, were switched to intravitreal aflibercept injections at intervals of up to 8 weeks. The primary outcome was the proportion of patients maintaining vision [<5 letter loss in visual acuity (VA)] at week 48. Secondary outcomes included the change in VA and central macular thickness (CMT) and the frequency of treatment necessary along with the safety of intravitreal aflibercept.
    Results: Forty-eight weeks after switching to aflibercept, 16/19 eyes had maintained VA. There was a median increase in vision of 5 letters [interquartile range (IQR): 0, 15;
    Conclusions: In this small cohort of eyes, switching to aflibercept seemed beneficial. The majority maintained or improved vision and eyes with IRF or SRF had significant reductions in macular edema. However, visual improvement was not always indicative of anatomical improvement.
    MeSH term(s) Aged ; Angiogenesis Inhibitors/therapeutic use ; Choroidal Neovascularization/drug therapy ; Choroidal Neovascularization/pathology ; Drug Substitution ; Female ; Humans ; Intravitreal Injections ; Macular Edema/pathology ; Male ; Middle Aged ; Prospective Studies ; Ranibizumab/therapeutic use ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/therapeutic use ; Subretinal Fluid/metabolism ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity
    Chemical Substances Angiogenesis Inhibitors ; Recombinant Fusion Proteins ; Vascular Endothelial Growth Factor A ; aflibercept (15C2VL427D) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; Ranibizumab (ZL1R02VT79)
    Language English
    Publishing date 2017-10-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2756329-7
    ISSN 2162-0989 ; 2162-0989
    ISSN (online) 2162-0989
    ISSN 2162-0989
    DOI 10.22608/APO.2017364
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Intraoperative 'floppy iris' syndrome and its relationship to tamsulosin: a urologist's guide.

    Lawrentschuk, Nathan / Bylsma, Guy W

    BJU international

    2006  Volume 97, Issue 1, Page(s) 2–4

    MeSH term(s) Antineoplastic Agents/adverse effects ; Humans ; Iris/drug effects ; Iris Diseases/chemically induced ; Male ; Prostatic Hyperplasia/drug therapy ; Sulfonamides/adverse effects
    Chemical Substances Antineoplastic Agents ; Sulfonamides ; tamsulosin (G3P28OML5I)
    Language English
    Publishing date 2006-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 1462191-5
    ISSN 1464-410X ; 1464-4096 ; 1358-8672
    ISSN (online) 1464-410X
    ISSN 1464-4096 ; 1358-8672
    DOI 10.1111/j.1464-410X.2006.05960.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Treatment of age-related macular degeneration.

    Bylsma, Guy W / Guymer, Robyn H

    Clinical & experimental optometry

    2005  Volume 88, Issue 5, Page(s) 322–334

    Abstract: Age-related macular degeneration (AMD) is the greatest cause of legal blindness in the western world. Established treatments include argon laser photocoagulation of extrafoveal choroidal neovascularisation (CNV) and photodynamic therapy of selected sub- ... ...

    Abstract Age-related macular degeneration (AMD) is the greatest cause of legal blindness in the western world. Established treatments include argon laser photocoagulation of extrafoveal choroidal neovascularisation (CNV) and photodynamic therapy of selected sub-foveal CNV. Newer approaches are targeting the angiogenic pathway in CNV development. Currently, other treatment modalities, such as radiotherapy and transpupillary thermotherapy do not have a clear role to play. Surgical options are experimental and only available in some centres for selected patients. Prevention of AMD remains elusive. Dietary supplements may have a role, while statins and prophylactic laser photocoagulation of drusen remain experimental. This paper explains the principles behind these approaches.
    MeSH term(s) Animals ; Humans ; Hyperthermia, Induced ; Laser Coagulation ; Macular Degeneration/therapy ; Photochemotherapy ; Photosensitizing Agents/therapeutic use ; Prognosis ; Treatment Outcome
    Chemical Substances Photosensitizing Agents
    Language English
    Publishing date 2005-09-09
    Publishing country Australia
    Document type Journal Article ; Review
    ZDB-ID 639275-1
    ISSN 0816-4622
    ISSN 0816-4622
    DOI 10.1111/j.1444-0938.2005.tb06716.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Transcriptomic and proteomic retinal pigment epithelium signatures of age-related macular degeneration.

    Senabouth, Anne / Daniszewski, Maciej / Lidgerwood, Grace E / Liang, Helena H / Hernández, Damián / Mirzaei, Mehdi / Keenan, Stacey N / Zhang, Ran / Han, Xikun / Neavin, Drew / Rooney, Louise / Lopez Sanchez, Maria Isabel G / Gulluyan, Lerna / Paulo, Joao A / Clarke, Linda / Kearns, Lisa S / Gnanasambandapillai, Vikkitharan / Chan, Chia-Ling / Nguyen, Uyen /
    Steinmann, Angela M / McCloy, Rachael A / Farbehi, Nona / Gupta, Vivek K / Mackey, David A / Bylsma, Guy / Verma, Nitin / MacGregor, Stuart / Watt, Matthew J / Guymer, Robyn H / Powell, Joseph E / Hewitt, Alex W / Pébay, Alice

    Nature communications

    2022  Volume 13, Issue 1, Page(s) 4233

    Abstract: There are currently no treatments for geographic atrophy, the advanced form of age-related macular degeneration. Hence, innovative studies are needed to model this condition and prevent or delay its progression. Induced pluripotent stem cells generated ... ...

    Abstract There are currently no treatments for geographic atrophy, the advanced form of age-related macular degeneration. Hence, innovative studies are needed to model this condition and prevent or delay its progression. Induced pluripotent stem cells generated from patients with geographic atrophy and healthy individuals were differentiated to retinal pigment epithelium. Integrating transcriptional profiles of 127,659 retinal pigment epithelium cells generated from 43 individuals with geographic atrophy and 36 controls with genotype data, we identify 445 expression quantitative trait loci in cis that are asssociated with disease status and specific to retinal pigment epithelium subpopulations. Transcriptomics and proteomics approaches identify molecular pathways significantly upregulated in geographic atrophy, including in mitochondrial functions, metabolic pathways and extracellular cellular matrix reorganization. Five significant protein quantitative trait loci that regulate protein expression in the retinal pigment epithelium and in geographic atrophy are identified - two of which share variants with cis- expression quantitative trait loci, including proteins involved in mitochondrial biology and neurodegeneration. Investigation of mitochondrial metabolism confirms mitochondrial dysfunction as a core constitutive difference of the retinal pigment epithelium from patients with geographic atrophy. This study uncovers important differences in retinal pigment epithelium homeostasis associated with geographic atrophy.
    MeSH term(s) Geographic Atrophy ; Humans ; Macular Degeneration/genetics ; Proteomics ; Retinal Pigment Epithelium ; Transcriptome/genetics
    Language English
    Publishing date 2022-07-26
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-022-31707-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Transcriptomic and proteomic retinal pigment epithelium signatures of age-related macular degeneration

    Anne Senabouth / Maciej Daniszewski / Grace E. Lidgerwood / Helena H. Liang / Damián Hernández / Mehdi Mirzaei / Stacey N. Keenan / Ran Zhang / Xikun Han / Drew Neavin / Louise Rooney / Maria Isabel G. Lopez Sanchez / Lerna Gulluyan / Joao A. Paulo / Linda Clarke / Lisa S. Kearns / Vikkitharan Gnanasambandapillai / Chia-Ling Chan / Uyen Nguyen /
    Angela M. Steinmann / Rachael A. McCloy / Nona Farbehi / Vivek K. Gupta / David A. Mackey / Guy Bylsma / Nitin Verma / Stuart MacGregor / Matthew J. Watt / Robyn H. Guymer / Joseph E. Powell / Alex W. Hewitt / Alice Pébay

    Nature Communications, Vol 13, Iss 1, Pp 1-

    2022  Volume 18

    Abstract: Age-related macular degeneration (AMD) is a leading cause of vision loss, and there is no approved treatment for AMD with geographic atrophy. Here, the authors used transcriptomic and proteomic analyses of patient induced pluripotent stem cell-derived ... ...

    Abstract Age-related macular degeneration (AMD) is a leading cause of vision loss, and there is no approved treatment for AMD with geographic atrophy. Here, the authors used transcriptomic and proteomic analyses of patient induced pluripotent stem cell-derived retinal pigment epithelium to better understand disease mechanisms.
    Keywords Science ; Q
    Language English
    Publishing date 2022-07-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article: Australian Angiogram Review Panel--monitoring the use of photodynamic therapy with verteporfin.

    Bylsma, Guy W / Harper, C Alex / Dutton, Francine / Johnson, Nick C / Beaumont, Paul / Guymer, Robyn H

    Clinical & experimental ophthalmology

    2006  Volume 34, Issue 6, Page(s) 550–556

    Abstract: Background: Photodynamic therapy with verteporfin for choroidal neovascularization (CNV) secondary to macular disease received an Australian government grant in 2002 to fund treatment for 3 years. Funding was restricted to subfoveal predominantly ... ...

    Abstract Background: Photodynamic therapy with verteporfin for choroidal neovascularization (CNV) secondary to macular disease received an Australian government grant in 2002 to fund treatment for 3 years. Funding was restricted to subfoveal predominantly classic CNV where visual acuity was at least 6/60. Access to this funding was via review of angiograms by an expert panel, the Angiogram Review Panel (ARP), managed by the Royal Australian and New Zealand College of Ophthalmologists.
    Methods: De-identified data from the ARP were obtained for the period June 2002 to April 2005 inclusive and the panel's outcomes were analysed. Health Insurance Commission and Department of Veteran Affairs data for photodynamic therapy for the same interval were also retrieved.
    Results: A total of 7198 submissions to the ARP were received for 5867 individuals in this period. Overall 86.6% eyes submitted were accepted for initial funding (treatments 2-4). There was no change over time in the percentage rejected during this period. The first reviewer accepted 77.2%. And the second reviewer accepted a further 7.7%. An additional 1.6% were accepted on appeal. It was estimated that 29.2% of this initial cohort received five or more treatments.
    Conclusions: The ARP data indicate an incidence of subfoveal predominantly classic CNV secondary to macular disease in Australia of about 2000 eyes per annum. Only one quarter of patients received five or more treatments. The panel provided a unique opportunity to estimate the 'whole of nation' incidence of predominantly classic subfoveal CNV secondary to macular disease and thus provides a firm foundation upon which to plan public health spending as new treatments become available.
    MeSH term(s) Australia ; Choroidal Neovascularization/drug therapy ; Choroidal Neovascularization/epidemiology ; Choroidal Neovascularization/etiology ; Drug Approval ; Drug Monitoring ; Humans ; Incidence ; Macular Degeneration/complications ; Photochemotherapy ; Photosensitizing Agents/therapeutic use ; Porphyrins/therapeutic use ; Retreatment
    Chemical Substances Photosensitizing Agents ; Porphyrins ; verteporfin (0X9PA28K43)
    Language English
    Publishing date 2006-08
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2014008-3
    ISSN 1442-9071 ; 1442-6404
    ISSN (online) 1442-9071
    ISSN 1442-6404
    DOI 10.1111/j.1442-9071.2006.01264.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Utilization of eye care services by Victorians likely to benefit from eye care.

    Bylsma, Guy W / Le, Anhchuong / Mukesh, Bickol N / Taylor, Hugh R / McCarty, Catherine A

    Clinical & experimental ophthalmology

    2004  Volume 32, Issue 6, Page(s) 573–577

    Abstract: Aim: To assess the utilization of eye care services by Australians most likely to benefit from eye assessment.: Methods: The Melbourne Visual Impairment Project was a population-based study that collected demographic, health and vision-related ... ...

    Abstract Aim: To assess the utilization of eye care services by Australians most likely to benefit from eye assessment.
    Methods: The Melbourne Visual Impairment Project was a population-based study that collected demographic, health and vision-related information including use of eye care services. A standardized detailed ophthalmic examination was performed. Utilization of eye care services by those who might most benefit from eye care was assessed and compared to the general population. These participants include those with undiagnosed glaucoma, unoperated visually significant cataract, undercorrected refractive error, diabetes mellitus, age-related macular degeneration and visual acuity < 6/12. Sociodemographic characteristics were assessed for their influence on eye care utilization among these participants.
    Results: A total of 4744 urban and rural residents participated (86% of those eligible) and 4612 (83% of total eligible) of these had a complete data set for the use of eye care services and were included. There were 933 participants (20.2%) who did not report eye assessment in the previous 5 years, and 891 participants (19.3%) had one or more aforementioned conditions potentially benefiting from eye care. Of these, between 34.4% and 59.4% reported no examination in the previous year and between 9% and 25% reported no examination within the previous 5 years. These participants were more likely to seek eye care within the short term (1 year) if they had a family history of eye disease, otherwise a noticed change in vision was the main influence in the longer term (2-5 years). Male participants, younger participants and those whose main spoken language was not English were less likely to seek eye care in the longer term.
    Conclusions: In Victoria 19% of those >40 years of age have potentially unmanaged eye disease including glaucoma, unoperated visually significant cataract, undercorrected refractive error, age-related macular degeneration, diabetes mellitus or visual acuity < 6/12. A substantial proportion of these report no eye assessment in the previous 1, 2 or 5 years or ever before. Younger age, male sex and main language other than English make assessment less likely. Many may have these conditions despite having had a recent eye assessment.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Delivery of Health Care/utilization ; Eye Diseases/epidemiology ; Eye Diseases/therapy ; Female ; Health Services/utilization ; Health Services Accessibility ; Humans ; Male ; Middle Aged ; Ophthalmology/statistics & numerical data ; Optometry/statistics & numerical data ; Prevalence ; Rural Population ; Urban Population ; Victoria/epidemiology ; Visually Impaired Persons/statistics & numerical data
    Language English
    Publishing date 2004-12
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2014008-3
    ISSN 1442-9071 ; 1442-6404
    ISSN (online) 1442-9071
    ISSN 1442-6404
    DOI 10.1111/j.1442-9071.2004.00905.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top